Ildiko Lingvay, M.D.

Ildiko Lingvay, M.D., M.P.H., M.S.C.S., is a Professor in the Department of Internal Medicine at UT Southwestern Medical Center and a member of the Division of Endocrinology. She holds a secondary appointment in the School of Public Health.

Originally from Bucharest, Romania, Dr. Lingvay earned her medical degree with honors at the University of Medicine and Pharmacy in Bucharest. She completed internal medicine residency training at Texas Tech University School of Medicine in Lubbock, Texas, followed by a fellowship in endocrinology, diabetes, and metabolism at UT Southwestern Medical Center. She holds a master's degree in public health from the UT Houston School of Public Health Dallas campus, as well as a master of science in clinical science with Distinction from UT Southwestern Medical Center.

Certified by the American Board of Internal Medicine in endocrinology and the American Board of Obesity Medicine, Dr. Lingvay joined the UT Southwestern faculty in 2005.

 Dr. Lingvay is a clinical investigator in the field of diabetes, obesity, and associated metabolic complications. She leads an active clinical research program in the Division of Endocrinology at UT Southwestern Medical Center. Her research interests span from pathophysiology to finding new treatment options to improve the lives of patients with such conditions. In 2007 she received a National Institute of Health Career Development Award to study the role of pancreatic triglyceride accumulation in beta-cell failure and type 2 diabetes and to further develop her career as a clinical investigator. 

She has published her work in many renowned journals like The Lancet, JAMA, New England Journal of Medicine, Circulation, JAMA Internal Medicine, and Diabetes Care. She has contributed to many textbooks in the field of diabetes and is on the editorial board of several journals. Dr. Lingvay has been invited to present lectures to her peers all over the world. She is an active member of the American Diabetes Association where she has served on several different committees.

Medical School

Carol Davila University of Medicine & Pharmacy (1998)

Internship/Residency

Texas Tech University Health Sciences Center (2002), Internal Medicine

Fellowship

UT Southwestern Medical Center (2005), Endocrinology & Metabolism

Other Post Graduate Training

University of Texas Health Science Center at Houston (2006)

Graduate School

University of Texas Health Science Center at Houston (2006), Public Health

Other Post Graduate Training

UT Southwestern Medical Center (2008)

Graduate School

UT Southwestern Medical Center (2008), Clinical Research

• Metabolic Syndrome
• Nonalcoholic Fatty Liver Disease (NAFLD)
• Nonalcoholic Steatohepatitis (NASH)
• Obesity
• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus

Featured Publications

Pharmacotherapies for Post-Bariatric Weight Regain: Real-World Comparative Outcomes.

Gazda CL, Clark JD, Lingvay I, Almandoz JP, Obesity (Silver Spring) 2021 May 29 5 829-836

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.

Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I, Lancet 2021 Mar 397 10278 971-984

Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study.

Lingvay I, Kirk AR, Lophaven S, Wolden ML, Shubrook JH, Diabetes Ther 2021 Feb

Once-Weekly Semaglutide in Adults with Overweight or Obesity.

Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF, N Engl J Med 2021 Feb

Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance.

Almandoz JP, Lingvay I, Morales J, Campos C, Clin Diabetes 2020 Oct 38 4 390-402

Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design.

Ryan DH, Lingvay I, Colhoun HM, Deanfield J, Emerson SS, Kahn SE, Kushner RF, Marso S, Plutzky J, Brown-Frandsen K, Gronning MOL, Hovingh GK, Holst AG, Ravn H, Lincoff AM, Am. Heart J. 2020 Jul 229 61-69

Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes.

Doria A, Galecki AT, Spino C, Pop-Busui R, Cherney DZ, Lingvay I, Parsa A, Rossing P, Sigal RJ, Afkarian M, Aronson R, Caramori ML, Crandall JP, de Boer IH, Elliott TG, Goldfine AB, Haw JS, Hirsch IB, Karger AB, Maahs DM, McGill JB, Molitch ME, Perkins BA, Polsky S, Pragnell M, Robiner WN, Rosas SE, Senior P, Tuttle KR, Umpierrez GE, Wallia A, Weinstock RS, Wu C, Mauer M, N. Engl. J. Med. 2020 06 382 26 2493-2503

Roux-en-Y Gastric Bypass Compared to Equivalent Diet Restriction: Mechanistic Insights into Diabetes Remission.

Pop LM, Mari A, Zhao TJ, Mitchell L, Burgess S, Li X, Adams-Huet B, Lingvay I Diabetes Obes Metab 2018 Mar

Hyposialylated IgG activates endothelial IgG receptor Fc?RIIB to promote obesity-induced insulin resistance.

Tanigaki K, Sacharidou A, Peng J, Chambliss KL, Yuhanna IS, Ghosh D, Ahmed M, Szalai AJ, Vongpatanasin W, Mattrey RF, Chen Q, Azadi P, Lingvay I, Botto M, Holland WL, Kohler JJ, Sirsi SR, Hoyt K, Shaul PW, Mineo C J. Clin. Invest. 2017 Nov

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T N. Engl. J. Med. 2016 Sep

 Featured Books

Diabetes in Diseases of Exocrine Pancreas. In Atypical Diabetes: Pathophysiology, Clinical Presentations, and Treatment Options

Gunasakaran U, Xamaropulous X, Jessica A, Tumyan A, Lingvay I (2018). American Diabetes Association

Inpatient Diabetes Management post-Bariatric Surgery. In Managing Diabetes and Hyperglycemia in the Hospital Setting: A Clinician's Guide

Alexanian S, Lingvay I (2016). American Diabetes Association

Management of Surgery and Anesthesia. In Therapy for Diabetes Mellitus and Related Disorders

Lingvay I, Aviles-Santa LM, Raskin P (2009). American Diabetes Association

Case 16: Misclassification of MODY 3 as Type 1. In Atypical Diabetes: Pathophysiology, Clinical Presentations, and Treatment Options

Song L, McNulty JN, Lingvay I (2018). American Diabetes Association

The Thyroid. In Textbook of Endocrine Physiology

Lingvay I, Holt S (2012). Oxford University Press Inc

Secondary Forms of Diabetes Mellitus. In American College of Physicians- Medicine

Lingvay I, Raskin P (2006). American College of Physicians

Non-insulin Pharmacological Therapies. In Type 2 Diabetes Mellitus: An Evidence-Based Approach to Practical Management

Lingvay I, Rhee C, Raskin P (2006).

• Jean W. Wilson Award for Scientific Mentorship
  (2019)
• Jean W. Wilson Award for Scientific Mentorship
  (2015)
• Jean W. Wilson Award for Scientific Mentorship
  (2011)

• American Diabetes Association
• American Federation for Medical Research
• European Association for the Study of Diabetes
• The Endocrine Society